The city of Dallas, Texas, currently has 76 active clinical trials seeking participants for Breast Cancer research studies.
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337
Recruiting
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Register for Updates
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Register for Updates
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT04152499
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma Small cell lung can... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2022
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation
NCT04491864
Recruiting
1.1. Primary Objectives To determine if MRI DWIBS can accurately identify suspicious lesions previously categorized on mammography and sonography as potentially malignant. We will also validate whether DWIBS-MRI ADC values can be used to accurately differentiate benign from malignant lesions. Additionally, because it is not known whether tumor type or growth rate (Ki67 values) will affect our results, we will include these parameters in our analysis. Once we validate the use of DWIBS-MRI ADC va... Read More
Gender:
Female
Ages:
30 years and above
Trial Updated:
07/27/2020
Locations: Baylor Scott & White Research Insitute, Dallas, Texas
Conditions: Breast Cancer
Register for Updates